COMP vs MMED: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: COMP is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COMP and MMED share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COMP and MMED exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Compass, Inc. is a tech-enabled residential real estate company that operates an owned-brokerage model in the United States. It recruits real estate agents onto a proprietary software platform that handles marketing, client management, and transaction workflow, and it earns revenue primarily as a share of the sales commissions its agents generate when homes change hands. Because agents keep most of each commission under negotiated splits, Compass keeps only a thin slice of a very large revenue number, so its margins are structurally low and its results track the volume of home sales closely. The company has expanded into adjacent services such as title, escrow, and mortgage referrals to capture more of each transaction.

Full COMP guide

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company building treatments for brain-health and psychiatric disorders from psychedelic and related compounds. Its lead asset is DT120 (formerly MM120), a pharmaceutically optimized, orally disintegrating tablet form of lysergide (LSD) D-tartrate being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). A Phase 2b study met its endpoints with durable anxiety improvement to Week 12, and the program carries FDA Breakthrough Therapy Designation for GAD, with results published in JAMA. The company also has earlier-stage programs including MM402 (an R-MDMA candidate) for autism spectrum disorder. In January 2026 the company rebranded to Definium Therapeutics and its Nasdaq ticker changed from MNMD to DFTX (the MMED symbol traced to its earlier Canadian listing).

Full MMED guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COMP drivers: Scale and market leadership; Improving profitability.
• MMED drivers: Three Phase 3 readouts in 2026; Deep cash runway.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Compass is highly exposed to the housing cycle: when mortgage rates rise or home sales slow, commission revenue falls quickly while many costs remain. For MMED, the company is unprofitable and cash-burning, with a Q1 2026 net loss reported near $77M (inflated by non-cash warrant fair-value changes) on operating expenses around $59M and no product revenue, so the multi-billion-dollar market value rests entirely on future clinical and regulatory success rather than current fundamentals.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COMP if you believe its drivers more; MMED if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COMP and MMED guides.

COMP. A residential brokerage like Compass reports a very large revenue number, but most of each commission is paid out to agents, so the figure to watch is adjusted EBITDA and free cash flow rather than top-line growth alone. The business is highly cyclical: transaction volume, and therefore revenue, swings with mortgage rates and home-sale activity, so a strong or weak quarter often reflects the housing market more than company-specific execution. Because margins are thin and GAAP results can flip between small profits and losses depending on stock-based compensation and merger costs, investors typically look at agent count, market share, EBITDA margin trend, and cash generation across a full cycle.

MMED. Mind Medicine (Definium) has no P/E because it is pre-revenue and unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality: only a fraction of the several-billion-dollar market value is backed by cash, with the remainder pricing the probability-weighted outcome of the 2026 Phase 3 readouts. Revenue is zero, which is normal for a clinical-stage biotech but means the shares trade on catalysts, not fundamentals. The reported Q1 net loss was materially distorted by a non-cash change in the fair value of financing warrants tied to the share-price rise, so operating cash burn is a better gauge of spending.

Headline figures (approximate, FY2025 results (full year ended December 2025) and Q1 2026): COMP shows revenue (fy2025) ~$6.96 billion (+23.7% YoY), principal agents ~21,000 (+~19% YoY), market share (q3 2025) ~5.6% (pre-Anywhere), adjusted ebitda (fy2025) ~$293 million (~4.2% margin); MMED shows market cap ~$4.7B (mid-2026), product revenue ~$0 (pre-commercial), net loss (q1 2026) ~$77M (incl. non-cash warrant charge), operating expenses (q1 2026) ~$59M (R&D ~$42M, G&A ~$18M).

COMP and MMED are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COMP and MMED exposure against your real portfolio. It is not an investment adviser.